Albertsons (ACI) is likely to post a modest upside to identical sales growth estimate of 2% in Q4, RBC Capital Markets said in an earnings preview Thursday.
The consensus estimate was 1.7% for the quarter, the report said. Albertsons will release its Q4 results April 15.
Despite a stable top-line growth, the company faces risks to the fiscal year 2025 adjusted EBITDA positioning, RBC said.
"Pharmacy mix shift will remain a drag and we believe 1H investments are needed to unlock growth potential across retail media and owned brands," the report said.
RBC kept its outperform rating with a $23 price target.
Price: 22.89, Change: +0.46, Percent Change: +2.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.